Optimi Health Sets 2027 Clinical Agenda; Expects First Ibogaine Capsules Soon
Optimi Health (OPTH) outlined 2027 clinical trials for OPTI-101 (psilocybin for MDD) and OPTI-201 (MDMA for PTSD). Phase 2b and 3 trials planned, with U.S. IND applications expected. Ibogaine capsule production to begin soon. Proposed shares-for-debt settlement of US$240,000. OPTH stock is down 5.06% to $1.96.


